The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation.
Uemura
N
N
Griffin
J D
JD
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D002470:Cell Survival / Q000187:drug effects* / Q000528:radiation effects; D016313:Genes, abl; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000528:radiation effects; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology*; D011839:Radiation, Ionizing; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016315:Proto-Oncogene Proteins c-abl